Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Liberty Global Ltd Class C (LBTYK) vs Novo Nordisk A/S (NVO) Price & Performance

Liberty Global Ltd Class CTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Liberty Global Ltd Class C vs Novo Nordisk A/S — how do they compare? Liberty Global Ltd Class C trades at $10.11 (market cap $3.48B), while Novo Nordisk A/S trades at $46.26 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 59.7× Liberty Global Ltd Class C's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.

LBTYKNVO
Market Cap
$3.48B$207.85B
Sector
TechnologyHealth
52-Week High
$12.67$63.98
52-Week Low
$9.59$35.29
Enterprise Value
$10.13B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Liberty Global Ltd Class C

LBTYK trades at $10.015, up 0.25% on the day, amid a bearish technical signal but strong analyst support. The stock shows mixed earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while the company navigates the Ziggo Group spin-off planned for 2027. Financially, it has a low P/S of 0.7 and P/B of 0.37, but negative net income and ROE highlight profitability challenges, offset by solid operating cash flow of $1.21 billion in 2025.

The outlook is cautiously optimistic, with the Ziggo Group listing in 2027 offering a potential catalyst, but persistent losses and competitive pressures pose risks. Analyst consensus is strongly bullish with 69% buy ratings, suggesting underlying value despite near-term headwinds.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Liberty Global Ltd Class C

Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.

Read more on LBTYK

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO